From the publishers of JADPRO

Myelofibrosis Resource Center

Advertisement

Thrombosis Research

Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib

Blood Neoplasia

Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis

Biomedicines

Clinical and molecular insights of arterial and venous thrombosis in myeloproliferative diseases-case-based narrative review

Clinical Case Reports

A case of myeloproliferative neoplasm-associated glomerulopathy in a patient with myelofibrosis

European Journal of Haematology

Efficacy of momelotinib in myelofibrosis patients: Results from a multicenter study

Blood

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis

Frontiers in Oncology

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: A case report and literature review

Tomography

Fat fraction MRI for longitudinal assessment of bone marrow heterogeneity in a mouse model of myelofibrosis

American Journal of Hematology

Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT

Journal of Hematology

Efficacy and safety of momelotinib in myelofibrosis: A systematic review and meta-analysis with a focus on anemia outcomes

Transplantation and Cellular Therapy

Risk stratification using DIPSS and splenomegaly in myelofibrosis treated with pre-transplant JAK inhibitors

European Journal of Haematology

Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine

Acta Haematologica

Impact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP studyImpact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP study

Clinical Lymphoma, Myeloma & Leukemia

Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

Journal of Inflammation Research

Prognostic implications of red blood cell distribution width to albumin ratio in myelofibrosis: A 10 year multicenter and retrospective study

International Journal of Hematology

Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

European Journal of Haematology

Time without transfusion reliance (TWiTR): Integrating survival quality into myelofibrosis treatment strategies based on the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Indian Journal of Hematology and Blood Transfusion

Renal impairment in myeloproliferative neoplasms: An under-reported complication

Blood

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

Nature Communications

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

Haematologica

Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms

Frontiers in Oncology

Case report: Sclerosing variant of extramedullary hematopoietic tumor primary arising in kidney, unexpected clinical and pathological presentation

Blood Work

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

Blood Neoplasia

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Ruxolitinib Discontinuation Syndrome in a Patient with Primary Myelofibrosis

The Management of Myelofibrosis-Related Anemia